- Raw materials
- Cephalosporins
- Ceftazidime
- Suppliers by country
- South Korea
Filters
Filter
Custom request?
Type
Production region
Qualifications
Country of origin
Ceftazidime API from South Korea Manufacturers & Suppliers
14 verified results
When insight is your advantage
Full data, full access, full negotiation power
Total market transparency
|
Supplier trade data access
|
Buyer / supplier flow comparison
Commercial-scale Suppliers
Distributor
Produced in
China|
Employees: 200+
|
Audit Report:
Certifications:
GMP
|
FDA|
CEP|
USDMF|
EDMF/ASMFAll certificates
GMP
FDA
CEP
USDMF
EDMF/ASMF
MSDS
BSE/TSE
ISO9001
WC
GDP
WHO-GMP
JDMF
KDMF
CoA
Distributor
Produced in
India|
Employees: 10
|
Audit Report:
Certifications:
GMP
|
FDA|
MSDS|
BSE/TSE|
CoAAll certificates
GMP
FDA
MSDS
BSE/TSE
CoA
Take control of your API sourcing
Submit a Special Inquiry and have Pharmaoffer activate verified suppliers.
Producer
Produced in
Unknown|
Audit Report:
Certifications:
GMP
|
FDA|
CEP|
USDMF|
coaAll certificates
GMP
FDA
CEP
USDMF
coa
Producer
Produced in
South Korea|
Audit Report:
Certifications:
JDMF
|
CoAAll certificates
JDMF
CoA
Producer
Produced in
Brazil|
Audit Report:
Certifications:
GMP
|
CEP|
CoAAll certificates
GMP
CEP
CoA
Producer
Produced in
Italy|
Audit Report:
Certifications:
USDMF
|
CoAAll certificates
USDMF
CoA
Get full market intelligence report
€399,-
All Ceftazidime data. Full access. Full negotiation power
Producer
Produced in
India|
Audit Report:
Certifications:
USDMF
|
CoAAll certificates
USDMF
CoA
Distributor
Produced in
Unknown|
Audit Report:
Certifications:
coa
All certificates
coa
Take control of your API sourcing
Producer
Produced in
France|
Audit Report:
Certifications:
GMP
|
CEP|
coaAll certificates
GMP
CEP
coa
Producer
Produced in
South Korea|
Audit Report:
Certifications:
GMP
|
CEP|
coaAll certificates
GMP
CEP
coa
Producer
Produced in
United Kingdom|
Audit Report:
Certifications:
GMP
|
CEP|
USDMF|
coaAll certificates
GMP
CEP
USDMF
coa
Producer
Produced in
South Korea|
Audit Report:
Certifications:
JDMF
|
CoAAll certificates
JDMF
CoA
Get full market intelligence report
€399,-
All Ceftazidime data. Full access. Full negotiation power
Producer
Produced in
China|
Audit Report:
Certifications:
GMP
|
FDA|
CEP|
USDMF|
coaAll certificates
GMP
FDA
CEP
USDMF
coa
WC
Distributor
Produced in
China|
Audit Report:
Certifications:
coa
All certificates
coa
When insight is your advantage
Full data, full access, full negotiation power
Total market transparency
|
Supplier trade data access
|
Buyer / supplier flow comparison
Trusted by 30,000+ registered pharma professionals:
Reach multinationals, SMEs, compounding pharmacies & more!
Ceftazidime | CAS No: 72558-82-8 | GMP-certified suppliers
A medication that treats severe respiratory, skin, urinary, intra-abdominal, and central nervous system infections caused by susceptible bacteria, including complex Gram-negative cases across key markets.
Therapeutic categories
AmidesAnti-Bacterial AgentsAnti-Infective AgentsAntibacterials for Systemic UseAntiinfectives for Systemic Usebeta Lactam Antibiotics
Generic name
Ceftazidime
Molecule type
small molecule
CAS number
72558-82-8
DrugBank ID
DB00438
Approval status
Approved drug
ATC code
J01DD02
Primary indications
- Ceftazidime is indicated for the treatment of lower respiratory tract infections, skin and skin structure infections, urinary tract infections, bacterial septicemia, bone and joint infections, gynecologic infections, intra-abdominal infections (including peritonitis), and central nervous system infections (including meningitis) caused by susceptible bacteria
- Ceftazidime is indicated in combination with [avibactam] to treat infections caused by susceptible Gram-negative organisms, including complicated intra-abdominal infections (cIAI), in conjunction with [metronidazole], and complicated urinary tract infections (cUTI), including pyelonephritis, in patients aged three months and older
- This combination is also indicated to treat hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) in patients aged 18 years and older
Product Snapshot
- Ceftazidime is a parenteral cephalosporin API supplied as injectable powders and solutions for IV/IM use
- It is used for a broad range of susceptible bacterial infections, including respiratory, skin/soft tissue, urinary, intra‑abdominal, CNS, and for resistant Gram‑negative infections when combined with avibactam
- It is approved in major regulated markets including the US, Canada, and the EU
Clinical Overview
Ceftazidime (CAS 72558-82-8) is a third‑generation cephalosporin used for the treatment of infections caused by susceptible Gram‑negative and selected Gram‑positive bacteria. Approved in 1985, it is indicated for lower respiratory tract infections, skin and skin structure infections, urinary tract infections, bacterial septicemia, bone and joint infections, gynecologic and intra‑abdominal infections including peritonitis, and central nervous system infections such as meningitis. In combination with avibactam, it is used for complicated intra‑abdominal infections with metronidazole, complicated urinary tract infections including pyelonephritis, and hospital‑acquired or ventilator‑associated bacterial pneumonia.
Ceftazidime exerts bactericidal activity through inhibition of penicillin‑binding proteins, with primary affinity for PBP3 in Gram‑negative organisms. This inhibition disrupts peptidoglycan cross‑linking, leading to loss of cell wall integrity. The compound demonstrates notable activity against Pseudomonas aeruginosa and other clinically relevant Gram‑negative species including Enterobacterales, Haemophilus influenzae, and Neisseria meningitidis. Activity against Gram‑positive organisms is limited compared with earlier‑generation cephalosporins, and intrinsic activity against anaerobes is low.
Following parenteral administration, ceftazidime distributes into extracellular fluids and achieves therapeutic concentrations in cerebrospinal fluid during meningeal inflammation. It is minimally metabolized and is primarily eliminated unchanged by the kidneys. Reduced renal function results in elevated and prolonged plasma concentrations, increasing the risk of neurotoxicity including seizures, encephalopathy, and neuromuscular excitability. Hypersensitivity reactions may occur, particularly in patients with β‑lactam allergy. As with other broad‑spectrum antibiotics, treatment may promote overgrowth of non‑susceptible organisms and Clostridioides difficile–associated diarrhea.
Ceftazidime is marketed globally in various parenteral formulations and as the fixed‑dose combination ceftazidime‑avibactam. For API procurement, suppliers should provide consistent impurity profiles, validated sterility controls, and confirmation of β‑lactam integrity to support formulation and regulatory requirements.
Ceftazidime exerts bactericidal activity through inhibition of penicillin‑binding proteins, with primary affinity for PBP3 in Gram‑negative organisms. This inhibition disrupts peptidoglycan cross‑linking, leading to loss of cell wall integrity. The compound demonstrates notable activity against Pseudomonas aeruginosa and other clinically relevant Gram‑negative species including Enterobacterales, Haemophilus influenzae, and Neisseria meningitidis. Activity against Gram‑positive organisms is limited compared with earlier‑generation cephalosporins, and intrinsic activity against anaerobes is low.
Following parenteral administration, ceftazidime distributes into extracellular fluids and achieves therapeutic concentrations in cerebrospinal fluid during meningeal inflammation. It is minimally metabolized and is primarily eliminated unchanged by the kidneys. Reduced renal function results in elevated and prolonged plasma concentrations, increasing the risk of neurotoxicity including seizures, encephalopathy, and neuromuscular excitability. Hypersensitivity reactions may occur, particularly in patients with β‑lactam allergy. As with other broad‑spectrum antibiotics, treatment may promote overgrowth of non‑susceptible organisms and Clostridioides difficile–associated diarrhea.
Ceftazidime is marketed globally in various parenteral formulations and as the fixed‑dose combination ceftazidime‑avibactam. For API procurement, suppliers should provide consistent impurity profiles, validated sterility controls, and confirmation of β‑lactam integrity to support formulation and regulatory requirements.
Identification & chemistry
| Generic name | Ceftazidime |
|---|---|
| Molecule type | Small molecule |
| CAS | 72558-82-8 |
| UNII | DZR1ENT301 |
| DrugBank ID | DB00438 |
Pharmacology
| Summary | Ceftazidime is a third‑generation cephalosporin that inhibits bacterial cell‑wall synthesis by binding key penicillin‑binding proteins, with primary activity at PBP3 in many Gram‑negative organisms. This blockade disrupts peptidoglycan cross‑linking and compromises cell integrity, producing bactericidal effects. Its pharmacology is characterized by broad Gram‑negative activity, relative stability to several β‑lactamases, and weaker activity against most Gram‑positive and anaerobic species. |
|---|---|
| Mechanism of action | The bacterial cell wall, which is located at the periphery of Gram-positive bacteria and within the periplasm of Gram-negative bacteria, comprises a glycopeptide polymer synthesized through cross-linking of glycans to peptide stems on alternating saccharides, which is known commonly as peptidoglycan.Cell wall formation, recycling, and remodelling require numerous enzymes, including a family of enzymes with similar active site character despite distinct and sometimes overlapping roles as carboxypeptidases, endopeptidases, transpeptidases, and transglycosylases, known as "penicillin-binding proteins" (PBPs). The number of PBPs differs between bacteria, in which some are considered essential and others redundant. In general, inhibition of one or more essential PBPs results in impaired cell wall homeostasis, loss of cell integrity, and is ultimately bactericidal. Ceftazidime is a semisynthetic third-generation cephalosporin with broad activity against numerous Gram-negative and some Gram-positive bacteria.Like other β-lactam antibiotics, ceftazidime exhibits its bactericidal effect primarily through direct inhibition of specific PBPs in susceptible bacteria._In vitro_ experiments in Gram-negative bacteria such as _Escherichia coli_, _Pseudomonas aeruginosa_, _Acinetobacter baumannii_, and _Klebsiella pneumoniae_ suggest that ceftazidime primarily binds to PBP3, with weaker binding to PBP1a/1b and PBP2 as well; although binding to other PBPs, such as PBP4, is detectable, the concentrations required are much greater than those achieved clinically.Similarly, ceftazidime showed binding to _Staphylococcus aureus_ PBP 1, 2, and 3 with a much lower affinity for PBP4.Recent data for _Mycobacterium abcessus_ suggest that ceftazidime can inhibit PonA1, PonA2, and PbpA at intermediate concentrations. |
| Pharmacodynamics | Ceftazidime is a semisynthetic, broad-spectrum, third-generation cephalosporin antibiotic that is bactericidal through inhibition of enzymes responsible for cell-wall synthesis, primarily penicillin-binding protein 3 (PBP3).Among cephalosporins, ceftazidime is notable for its resistance to numerous β-lactamases and its broad spectrum of activity against Gram-negative bacteria, including _Pseudomonas aeruginosa_.However, it is less active than first- and second-generation cephalosporins against _Staphylococcus aureus_ and other Gram-positive bacteria and also has low activity against anaerobes.Ceftazidime has confirmed activity against clinically relevant Gram-negative bacteria including _Citrobacter_ spp., _Enterobacter_ spp., _Klebsiella_ spp., _Proteus_ spp., _Serratia spp., _Escherichia coli_, _Haemophilus influenzae_, _Neisseria meningitidis_, _Pseudomonas aeruginosa_, and some Gram-positive bacteria including _Staphylococcus_ spp. and _Streptococcus_ spp. There are also _in vitro_ data for ceftazidime efficacy against a wide variety of other bacteria, such as _Acinetobacter baumannii_ and _Neisseria gonorrhoeae_, but no clear clinical studies to support the use of ceftazidime for infections caused by these bacteria. Although β-lactam antibiotics like ceftazidime are generally well tolerated, there remains a risk of serious acute hypersensitivity reactions, which is higher in patients with a known allergy to ceftazidime or any other β-lactam antibiotic. As with all antibiotics, ceftazidime may result in the overgrowth of non-susceptible organisms and potentially serious effects including _Clostridium difficile_-associated diarrhea (CDAD); CDAD should be considered in patients who develop diarrhea and, in confirmed cases, supportive care initiated immediately. Ceftazidime is primarily renally excreted such that high and prolonged serum concentrations can occur in patients with renal insufficiency, leading to seizures, nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia. Treatment may lead to the development or induction of resistance with a risk of treatment failure. Periodic susceptibility testing should be considered, and monotherapy failure may necessitate the addition of another antibiotic such as an aminoglycoside. Cephalosporin use may decrease prothrombin activity, which may be improved by exogenous vitamin K. Inadvertent intra-arterial administration of ceftazidime may result in distal necrosis. |
Targets
| Target | Organism | Actions |
|---|---|---|
| Peptidoglycan synthase FtsI | Escherichia coli (strain K12) | inhibitor |
| Penicillin-binding protein 1A | Escherichia coli (strain K12) | inhibitor |
| Penicillin-binding protein 1B | Escherichia coli (strain K12) | inhibitor |
ADME / PK
| Absorption | Ceftazidime administered intravenously in healthy males produced mean C<sub>max</sub> values of between 42 and 170 μg/mL for doses between 500 mg and 2 g, and are reached immediately following the end of the infusion period.The C<sub>max</sub> for 1 g of ceftazidime administered intramuscularly is attained approximately one hour following injection and is between 37 and 43 mg/L.Following intramuscular administration of 500 mg and 1 g of ceftazidime, the serum concentration remained above 4 μg/mL for six and eight hours, respectively. Ceftazidime C<sub>max</sub> and AUC show linear proportionality to the dose over the therapeutic range.In individuals with normal renal function, ceftazidime given intravenously every eight hours for 10 days as either 1 or 2 g doses showed no accumulation. |
|---|---|
| Half-life | Ceftazidime has an elimination half-life of 1.5-2.8 hours in healthy subjects.As ceftazidime is primarily renally excreted, its half-life is significantly prolonged in patients with renal impairment.In patients with creatinine clearance < 12 mL/min, the half-life is prolonged to between 14 and 30 hours. |
| Protein binding | Ceftazidime plasma protein binding ranges from 5-22.8% (typically less than 10%) and is independent of concentration.Ceftazidime has been shown to bind human serum albumin. |
| Metabolism | Ceftazidime is not appreciably metabolized. |
| Route of elimination | Approximately 80% to 90% of an intramuscular or intravenous dose of ceftazidime is excreted unchanged by the kidneys over a 24-hour period. When administered intravenously, 50% of the dose appears in the urine within two hours, with another 32% of the dose appearing by eight hours post-administration. |
| Volume of distribution | Ceftazidime has a volume of distribution of 15-20 L. |
| Clearance | The mean renal clearance of ceftazidime in healthy subjects ranges from 72 to 141 mL/min while the calculated plasma clearance is approximately 115 mL/min. |
Formulation & handling
- Formulated exclusively for parenteral use; supplied as a lyophilized powder requiring reconstitution for IM or IV administration due to poor oral bioavailability.
- Highly hydrophilic small‑molecule cephalosporin; low logP and modest aqueous solubility necessitate appropriate diluents to ensure complete dissolution before use.
- Solution stability is limited by hydrolysis of the β‑lactam ring, so reconstituted solutions require controlled pH and timely use to maintain potency.
Regulatory status
| Lifecycle | Several early U.S. patents have expired while others extend through 2030–2031, indicating a product transitioning from partial loss of exclusivity toward a later stage of its lifecycle. With availability across the US, Canada, and the EU, the API is marketed in mature regions where competition is expected to increase as remaining protections expire. |
|---|
| Markets | US, Canada, EU |
|---|
Supply Chain
| Supply chain summary | Ceftazidime is produced and packaged by multiple established pharmaceutical manufacturers, indicating no single dominant originator and a mature, widely distributed supply base. Branded and unbranded products are marketed across the US, Canada, and the EU, reflecting broad global availability. While core ceftazidime substance patents have long expired, the presence of later‑expiring US patents related to specific formulations or combinations suggests that most forms face existing generic competition, with some protected presentations remaining under patent. |
|---|
Safety
| Toxicity | Ceftazidime overdosage has occurred in patients with renal failure. Reactions included seizure activity, encephalopathy, asterixis, neuromuscular excitability, and coma. Patients who receive an acute overdosage should be carefully observed and given supportive treatment. In the presence of renal insufficiency, hemodialysis or peritoneal dialysis may aid in the removal of ceftazidime from the body. |
|---|
High Level Warnings:
- Overexposure has been associated with neurotoxic manifestations such as seizures, encephalopathy, asterixis, neuromuscular excitability, and coma, with increased risk under renal impairment
- Accumulation may occur in reduced renal function
- Dialysis procedures can enhance clearance, indicating relevance for process design and impurity or residual‑risk assessments
Ceftazidime is a type of Cephalosporins
Cephalosporins are a class of pharmaceutical active ingredients (APIs) widely used in the field of antibiotics. They belong to the beta-lactam family, which also includes penicillins. Cephalosporins are derived from a fungus called Acremonium cephalosporium and are known for their potent antimicrobial properties.
These APIs are commonly used to treat a wide range of bacterial infections, including respiratory tract infections, skin and soft tissue infections, urinary tract infections, and even meningitis. Cephalosporins work by inhibiting the synthesis of bacterial cell walls, leading to the disruption of bacterial growth and ultimately their destruction.
Cephalosporins are classified into generations based on their antimicrobial spectrum and activity against specific bacteria. The first-generation cephalosporins are effective against Gram-positive bacteria, while subsequent generations show broader activity against both Gram-positive and Gram-negative bacteria.
Pharmaceutical companies manufacture cephalosporins in various formulations, including tablets, capsules, injectable solutions, and suspensions. They are often prescribed by healthcare professionals and are available under different brand names in the market.
It is important to note that like other antibiotics, cephalosporins should be used judiciously to prevent the development of antibiotic resistance. Proper dosage and adherence to treatment guidelines are crucial to maximize their effectiveness and minimize the risk of resistance.
In conclusion, cephalosporins are a vital category of APIs widely used in the treatment of bacterial infections. Their broad spectrum of activity and effectiveness make them an essential tool in modern medicine.
Ceftazidime API manufacturers & distributors
Compare qualified Ceftazidime API suppliers worldwide. We currently have 14 companies offering Ceftazidime API, with manufacturing taking place in 8 different countries. Use the table below to review supplier type, countries of origin, certifications, product portfolio and GMP audit availability.
| Supplier | Type | Country | Product origin | Certifications | Portfolio |
|---|---|---|---|---|---|
| ACS Dobfar | Producer | Italy | Italy | CoA, USDMF | 36 products |
| Antibióticos do Brasila | Producer | Brazil | Brazil | CEP, CoA, GMP | 3 products |
| Arshine Pharmaceutical Co... | Distributor | China | China | BSE/TSE, CEP, CoA, EDMF/ASMF, FDA, GDP, GMP, ISO9001, JDMF, KDMF, MSDS, USDMF, WC, WHO-GMP | 176 products |
| CJ CheilJedang | Producer | South Korea | South Korea | CoA, JDMF | 2 products |
| Flavine | Distributor | Germany | Unknown | CoA | 83 products |
| Glaxosmithkline | Producer | United Kingdom | United Kingdom | CEP, CoA, GMP, USDMF | 19 products |
| Hanmi Fine Chemical | Producer | South Korea | South Korea | CEP, CoA, GMP | 18 products |
| Parabolic Drugs | Producer | India | India | CoA, USDMF | 11 products |
| Qilu Antibiotics | Producer | China | China | CEP, CoA, FDA, GMP, USDMF, WC | 33 products |
| Sandoz | Producer | Austria | Unknown | CEP, CoA, FDA, GMP, USDMF | 58 products |
| Shaoxing Hantai Pharma | Distributor | China | China | CoA | 162 products |
| Solvay Operations | Producer | France | France | CEP, CoA, GMP | 2 products |
| Tenatra Exports Private L... | Distributor | India | India | BSE/TSE, CoA, FDA, GMP, MSDS | 263 products |
| Yungjin Pharmaceutical | Producer | South Korea | South Korea | CoA, JDMF | 10 products |
When sending a request, specify which Ceftazidime API quality you need: for example EP (Ph. Eur.), USP, JP, BP, or another pharmacopoeial standard, as well as the required grade (base, salt, micronised, specific purity, etc.).
Use the list above to find high-quality Ceftazidime API suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our help page to learn more about sourcing APIs via Pharmaoffer.
Frequently asked questions about Ceftazidime API
Sourcing
What matters most when sourcing GMP-grade Ceftazidime?
Key considerations are confirmation of GMP compliance and alignment with regulatory expectations in the US, Canada, and the EU. Suppliers should provide complete quality and regulatory documentation to support assessment of manufacturing controls, packaging, and distribution. It is also important to ensure that the specific Ceftazidime presentation does not conflict with any still‑active formulation or combination patents. The broad, mature supply base allows evaluation of multiple qualified manufacturers.
Which documents are typically required when sourcing Ceftazidime API?
Request the core API documentation set: CoA (14 companies), GMP (8 companies), CEP (7 companies), USDMF (6 companies), FDA (4 companies). Confirm versions and validity dates match the destination market to avoid delays in qualification.
Which manufacturers are known to produce Ceftazidime API?
Known or reported manufacturers for Ceftazidime: Arshine Pharmaceutical Co., Limited, Tenatra Exports Private Limited. Evaluate their GMP history, scale, and regional coverage before requesting dossiers or allocating demand.
How can I request quotes for Ceftazidime API from GMP suppliers?
Submit quote requests through the supplier listings with your specs and required documents (specifications, target volume, delivery timeline, and destination). Providing consistent details upfront speeds comparable offers and clarifies technical feasibility.
Is a GMP audit report available for Ceftazidime manufacturers?
Audit reports may be requested for Ceftazidime: 3 GMP audit reports available. Confirm the scope and recency of any audit before relying on it for qualification decisions.
How many suppliers offer Ceftazidime API on Pharmaoffer?
Reported supplier count for Ceftazidime: 14 verified suppliers. Filter listings by certifications, regions, and delivery options to match your qualification plan.
Which countries are known to manufacture Ceftazidime API?
Production countries reported for Ceftazidime: China (3 producers), South Korea (3 producers), India (2 producers). Knowing the manufacturing geography helps anticipate logistics lead times and import compliance needs.
Which certifications do suppliers of Ceftazidime usually hold?
Common certifications for Ceftazidime suppliers: CoA (14 companies), GMP (8 companies), CEP (7 companies), USDMF (6 companies), FDA (4 companies). Always verify issuing authorities and expiry dates when reviewing audit packages.
Technical
What is Ceftazidime (CAS 72558-82-8) used for?
Ceftazidime is used to treat infections caused by susceptible Gram‑negative and selected Gram‑positive bacteria. It is indicated for lower respiratory tract, urinary tract, skin and skin structure, bone and joint, gynecologic, intra‑abdominal, bloodstream, and central nervous system infections. In combination with avibactam, it is used for complicated intra‑abdominal infections with metronidazole, complicated urinary tract infections including pyelonephritis, and hospital‑ or ventilator‑associated bacterial pneumonia.
Which therapeutic class does Ceftazidime fall into?
Ceftazidime belongs to the following therapeutic categories: Amides, Anti-Bacterial Agents, Anti-Infective Agents, Antibacterials for Systemic Use, Antiinfectives for Systemic Use. This positioning helps teams compare alternative APIs, anticipate pharmacology expectations, and align early research priorities.
What conditions is Ceftazidime mainly prescribed for?
The primary indications for Ceftazidime: Ceftazidime is indicated for the treatment of lower respiratory tract infections, skin and skin structure infections, urinary tract infections, bacterial septicemia, bone and joint infections, gynecologic infections, intra-abdominal infections (including peritonitis), and central nervous system infections (including meningitis) caused by susceptible bacteria, Ceftazidime is indicated in combination with [avibactam] to treat infections caused by susceptible Gram-negative organisms, including complicated intra-abdominal infections (cIAI), in conjunction with [metronidazole], and complicated urinary tract infections (cUTI), including pyelonephritis, in patients aged three months and older, This combination is also indicated to treat hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) in patients aged 18 years and older. These use cases frame the target patient populations and help prioritize formulation and safety evaluations.
How does Ceftazidime work?
The bacterial cell wall, which is located at the periphery of Gram-positive bacteria and within the periplasm of Gram-negative bacteria, comprises a glycopeptide polymer synthesized through cross-linking of glycans to peptide stems on alternating saccharides, which is known commonly as peptidoglycan.Cell wall formation, recycling, and remodelling require numerous enzymes, including a family of enzymes with similar active site character despite distinct and sometimes overlapping roles as carboxypeptidases, endopeptidases, transpeptidases, and transglycosylases, known as "penicillin-binding proteins" (PBPs). The number of PBPs differs between bacteria, in which some are considered essential and others redundant. In general, inhibition of one or more essential PBPs results in impaired cell wall homeostasis, loss of cell integrity, and is ultimately bactericidal.
Ceftazidime is a semisynthetic third-generation cephalosporin with broad activity against numerous Gram-negative and some Gram-positive bacteria.Like other β-lactam antibiotics, Ceftazidime exhibits its bactericidal effect primarily through direct inhibition of specific PBPs in susceptible bacteria._In vitro_ experiments in Gram-negative bacteria such as _Escherichia coli_, _Pseudomonas aeruginosa_, _Acinetobacter baumannii_, and _Klebsiella pneumoniae_ suggest that Ceftazidime primarily binds to PBP3, with weaker binding to PBP1a/1b and PBP2 as well; although binding to other PBPs, such as PBP4, is detectable, the concentrations required are much greater than those achieved clinically.Similarly, Ceftazidime showed binding to _Staphylococcus aureus_ PBP 1, 2, and 3 with a much lower affinity for PBP4.Recent data for _Mycobacterium abcessus_ suggest that Ceftazidime can inhibit PonA1, PonA2, and PbpA at intermediate concentrations.
What should someone know about the safety or toxicity profile of Ceftazidime?
Ceftazidime’s safety profile is characterized mainly by neurotoxic effects such as seizures, encephalopathy, asterixis, neuromuscular excitability, and coma, particularly when plasma levels accumulate. Accumulation is most likely in renal impairment because the drug is eliminated unchanged by the kidneys, and dose adjustment or dialysis may be relevant to limit exposure. Hypersensitivity reactions can occur in patients with β‑lactam allergy. As with other broad‑spectrum antibiotics, treatment may lead to overgrowth of non‑susceptible organisms and Clostridioides difficile–associated diarrhea.
What are important formulation and handling considerations for Ceftazidime as an API?
Important considerations include its exclusive use in parenteral formulations, requiring reconstitution of the lyophilized powder with suitable diluents to achieve complete dissolution. Because Ceftazidime is highly hydrophilic with modest aqueous solubility, appropriate solvent selection is necessary to ensure proper solution formation. The β‑lactam ring is susceptible to hydrolysis, so reconstituted solutions need controlled pH and prompt use to maintain stability. Avoiding prolonged storage after reconstitution helps preserve potency.
Is Ceftazidime a small molecule?
Ceftazidime is classified as a small molecule. That classification shapes process design, impurity profiling, and analytical control strategies.
Are there special stability concerns for oral Ceftazidime?
Ceftazidime is not formulated for oral administration, so oral stability concerns do not apply. Its stability issues relate to hydrolysis of the β‑lactam ring in reconstituted parenteral solutions, which require appropriate pH control and timely use to maintain potency.
Regulatory
Where is Ceftazidime approved or in use globally?
Ceftazidime is reported as approved in the following major regions: US, Canada, EU. Understanding geographic coverage informs regulatory filings, supply planning, and risk assessments before escalating procurement.
What’s the regulatory and patent landscape for Ceftazidime right now?
Ceftazidime is regulated for use in the United States, Canada, and the European Union. Its patent status is governed by the respective intellectual property frameworks in each region and may differ by jurisdiction.
Pharmaoffer
How does Pharmaoffer’s Smart Sourcing Service help with Ceftazidime procurement?
Pharmaoffer's Smart Sourcing Service coordinates compliant suppliers, documentation, and competitive quotes for Ceftazidime. It centralizes outreach, follow-ups, and document validation to shorten procurement timelines.
Is Ceftazidime included in the PRO Data Insights coverage?
PRO Data Insights coverage for Ceftazidime: 1538 verified transactions across 390 suppliers and 264 buyers worldwide. Use the dataset to benchmark suppliers and monitor regulatory activity where available.
Where can I access the API market report for Ceftazidime?
Market report availability for Ceftazidime: Report Available. The report highlights demand trends, pricing drivers, and supplier landscape insights for procurement planning.
